Without prophylaxis 5-10% of patients having elective hip replacement develop clinically important venous thrombosis and about 5% develop symptomatic embolism, which is fatal in up to 0-5%. ' venography could then be treated to prevent extension and embolism.
Results
Patients had a mean age of 70 (SD 9) years (range 52-94 years) and a mean weight of 72 (SD 15) kg (range 44-119 kg); 31 (89%) hip replacements and three of 10 knee replacements were done under general anaesthesia; 20 (57%) hips were replaced with cemented prostheses and 24 (69%) replacements were done with a lateral approach. The prothrombin ratio (international normalised ratio) was normal on the day of surgery (one patient with a ratio of 17 on the day before surgery remained in the trial after the ratio fell below 1 5 after vitamin K was given), increased slightly on day 3 but fell on day 7. Surgical and postoperative bleeding were not excessive. The rate of venous thrombosis was 40% after hip replacement and 70% after knee replacement (table).
Discussion
Our trial was a relatively unambitious pilot study, methodologically handicapped by its lack of randomised controls. Nevertheless, our findings strongly suggest that minidose warfarin cannot be recommended prophylactically in patients having elective major joint replacement.
We chose a cohort study because routine venography after hip replacement discloses a stable rate of thrombosis of about 50% in untreated patients,' giving us confidence that a pilot study would quickly indicate if a randomised trial would be worth while. In the event, the rate after minidose warfarin was similar to that in previous controls having hip or knee replacement ( 
